Meihui Fan Sells Shares of ZEPP

Meihui Fan, the Chief Technology Officer of ZEPP, sold 440,000 shares of the company on June 26, 2026. This transaction was not part of a pre-planned trading program. ZEPP shares were trading at approximately $4.73 on Tuesday.

Other Institutional Activity in ZEPP

Several institutional investors made changes to their holdings in ZEPP. FIL LTD increased its stake by 91,596 shares, bringing its total to 717,352 shares valued at about $8.57 million, marking a 14.6% increase. Morgan Stanley also grew its position by 97,397 shares, ending with 707,691 shares worth approximately $8.46 million, reflecting a 16.0% increase. Meanwhile, Point72 Asset Management slightly decreased its holdings by 294 shares, maintaining 577,676 shares valued at around $6.90 million, a minor 0.1% decrease. Millennium Management reduced its position by 24,322 shares, holding 342,504 shares valued at $4.09 million, a 6.6% decrease. Monolith Management added 40,182 shares to its portfolio, now holding 173,847 shares worth $2.08 million, which is a 30.1% increase.

Insider Buying and Selling at Zepp Health Corporation

In addition to Meihui Fan's sale, there were other notable insider transactions at ZEPP. On the same day, Meihui Fan also purchased 520,000 shares. Deng Cheng, the Chief Financial Officer, was active as well, buying 22,875 shares and selling 9,836 shares at $4.61 each. Earlier, on April 1, 2026, Deng Cheng had purchased 366,000 shares.

Analysts Set New Price Targets

Citi maintained its 'buy' rating for ZEPP on August 21, 2023, with a price target of $3.10.

Bottom Line

The recent insider and institutional activities at ZEPP highlight active trading interest in the company. While Meihui Fan's sale of shares is notable, it occurred alongside other significant insider transactions. Institutional investors like FIL LTD and Morgan Stanley have shown confidence by increasing their stakes. As always, remember that these filings reflect past actions and may not indicate current positions.